ATE288749T1 - Verwendung von kannabidiol als entzündunghemmende mittel - Google Patents

Verwendung von kannabidiol als entzündunghemmende mittel

Info

Publication number
ATE288749T1
ATE288749T1 AT99915942T AT99915942T ATE288749T1 AT E288749 T1 ATE288749 T1 AT E288749T1 AT 99915942 T AT99915942 T AT 99915942T AT 99915942 T AT99915942 T AT 99915942T AT E288749 T1 ATE288749 T1 AT E288749T1
Authority
AT
Austria
Prior art keywords
cannabidiol
inflammatory agents
cannabinoids
inflammatory diseases
treating inflammatory
Prior art date
Application number
AT99915942T
Other languages
English (en)
Inventor
Marc Feldmann
Anne-Marie Malfait
Ruth Gallily
Raphael Mechoulam
Original Assignee
Kennedy Rheumatology Inst
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kennedy Rheumatology Inst, Yissum Res Dev Co filed Critical Kennedy Rheumatology Inst
Application granted granted Critical
Publication of ATE288749T1 publication Critical patent/ATE288749T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT99915942T 1998-04-14 1999-04-14 Verwendung von kannabidiol als entzündunghemmende mittel ATE288749T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9807639.1A GB9807639D0 (en) 1998-04-14 1998-04-14 Anti-inflammatory agents
PCT/GB1999/001140 WO1999052524A1 (en) 1998-04-14 1999-04-14 Use of cannabinoids as anti-inflammatory agents

Publications (1)

Publication Number Publication Date
ATE288749T1 true ATE288749T1 (de) 2005-02-15

Family

ID=10830115

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99915942T ATE288749T1 (de) 1998-04-14 1999-04-14 Verwendung von kannabidiol als entzündunghemmende mittel

Country Status (12)

Country Link
US (1) US6410588B1 (de)
EP (1) EP1071417B1 (de)
JP (1) JP2002511411A (de)
AT (1) ATE288749T1 (de)
AU (1) AU757945B2 (de)
CA (1) CA2328368C (de)
DE (1) DE69923671T2 (de)
DK (1) DK1071417T3 (de)
ES (1) ES2241277T3 (de)
GB (1) GB9807639D0 (de)
IL (1) IL138979A0 (de)
WO (1) WO1999052524A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999053917A1 (en) 1998-04-21 1999-10-28 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Cannabinoids as antioxidants and neuroprotectants
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
AU3910700A (en) * 1999-03-22 2000-10-09 Immugen Pharmaceuticals, Inc. Treatment of immune diseases
DE60116359T2 (de) * 2000-10-31 2006-09-28 Pharma Mar S.A. Kahalalid f formulierung
EP1206934A1 (de) * 2000-11-15 2002-05-22 B. Braun Melsungen Ag Blockade von Natriumkanälen mit Phenolderivaten
US10004684B2 (en) 2001-02-14 2018-06-26 Gw Pharma Limited Pharmaceutical formulations
GB0202385D0 (en) * 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions
US8034843B2 (en) 2002-02-01 2011-10-11 Gw Pharma Limited Compositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions
IL148244A0 (en) 2002-02-19 2002-09-12 Yissum Res Dev Co Anti-nausea and anti-vomiting activity of cannabidiol compounds
WO2003075917A1 (en) 2002-03-08 2003-09-18 Signal Pharmaceuticals, Inc. Combination therapy for treating, preventing or managing proliferative disorders and cancers
KR101008609B1 (ko) * 2002-08-14 2011-01-17 지더블유 파마 리미티드 점막투여용 칸나비노이드 액체 제형
US7067155B2 (en) * 2003-01-03 2006-06-27 Tbni, Inc. Anti-inflammatory humate compositions and methods of use thereof
IL160420A0 (en) * 2004-02-16 2004-07-25 Yissum Res Dev Co Treating or preventing diabetes with cannabidiol
WO2006024958A2 (en) * 2004-08-09 2006-03-09 Novimmune S.A. Cannabinoid compositions and methods of use thereof
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
US20100158973A1 (en) 2006-03-13 2010-06-24 Hadasit Medical Research Services & Development Llimited Therapeutic uses of cannabidiol compounds
GB2438682A (en) * 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
GB2448535A (en) * 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
GB2450741A (en) * 2007-07-05 2009-01-07 Gw Pharma Ltd Cannabinoid containing plant extracts in the treatment of inflammatory bowel disease
ATE493977T1 (de) * 2007-10-02 2011-01-15 Vivacell Biotechnology Espana S L Zusammensetzung mit nicht-psychotropen cannabinoiden zur behandlung von entzündungserkrankungen
GB2496688B (en) 2011-11-21 2016-06-29 Gw Pharma Ltd Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases
US9889100B2 (en) 2013-05-02 2018-02-13 Mor Research Applications Ltd. Cannabidiol for treatment of severe and refractory graft-versus-host disease
ES2788744T3 (es) 2013-05-02 2020-10-22 Mor Research Applic Ltd Cannabidiol para la prevención y el tratamiento de la enfermedad de injerto contra huésped
US10172786B2 (en) * 2014-12-16 2019-01-08 Axim Biotechnologies, Inc. Oral care composition comprising cannabinoids
EP3277260B1 (de) 2015-04-01 2021-05-12 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) Pflanzenextrakte aus erodium crassifolium l'her und verwendungen davon
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
WO2017066747A1 (en) * 2015-10-16 2017-04-20 Scythian Biosciences Inc. Methods and compositions for treating gastrointestinal inflammation
WO2017160923A1 (en) * 2016-03-15 2017-09-21 Royal Oil Colorado Llc Formulations of argan oil and cannabidiol
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
US10399920B2 (en) 2016-06-01 2019-09-03 S&B Pharma, Inc. Crystalline form of cannabidiol
US10835501B2 (en) 2016-10-01 2020-11-17 Indication Bioscience Llc Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
CA3042493A1 (en) 2016-11-02 2018-05-11 To Pharmaceuticals Llc Combination therapy of cbd and copaxone
WO2018163163A1 (en) 2017-03-05 2018-09-13 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Compositions and methods for treating inflammatory diseases
CA3068879C (en) * 2017-07-18 2022-12-13 Deyi Pharmaceutical Ltd. Use of cannabidol in treatment of pulmonary hypertension
EP3668500A4 (de) * 2017-08-14 2021-04-28 Zynerba Pharmaceuticals, Inc. Verfahren zur behandlung von osteoarthritis mit transdermalem cannabidiolgel
US11110056B1 (en) 2018-05-03 2021-09-07 Actual Natural Health & Wellness Products, Inc. Nasal hygiene method and composition
US10945982B1 (en) * 2018-05-03 2021-03-16 Paul A. Lobel Nasal hygiene method and composition
CA3116858A1 (en) * 2018-10-16 2020-04-23 Systamedic Inc. Novel compositions for the treatment of inflammatory diseases
US11026888B1 (en) 2019-01-04 2021-06-08 Nutrition Therapeutics, Inc. Functional beverage compositions and methods of using and making same
CA3128400A1 (en) * 2019-02-11 2020-08-20 John R. Chancey Methods of making and using phytocannabinoids complexed with a protein, peptide, amino acid, polysaccharide, disaccharide, or monosaccharide
CA3132856A1 (en) * 2019-04-30 2020-11-05 Elliot Altman Cannabinoid compositions and methods of using
WO2021011935A1 (en) * 2019-07-18 2021-01-21 Direct Biologics, Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
CA3169702A1 (en) * 2020-04-02 2021-10-07 Joel Bradley LATHAM Methods and compositions for treating or preventing an inflammatory condition
MX2022014197A (es) * 2020-05-11 2022-12-07 Add Advanced Drug Delivery Tech Ltd Usos y formulaciones de cannabinoides.
IL298059A (en) * 2020-05-11 2023-01-01 Add Advanced Drug Delivery Tech Ltd Uses and formulations of cannabinoids
CA3199891A1 (en) 2020-11-24 2022-06-02 Ruth Gallily Cannabinoid derivatives and their use for the treatment of inflammation and/or pain and/or obesity
IL309886A (en) * 2021-07-15 2024-03-01 Incannex Healthcare Ltd A preparation containing cannabidiol and hydroxychloroquine in a combined capsule at a fixed dose
WO2023156983A1 (en) 2022-02-21 2023-08-24 Universidade Nova De Lisboa Compounds and compositions for neurodegenerative diseases
EP4230201A1 (de) 2022-02-21 2023-08-23 Universidade Nova De Lisboa Zusammensetzungen zur behandlung von neurodegenerativen erkrankungen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL48824A (en) 1976-01-12 1980-05-30 Yissum Res Dev Co Pharmaceutical compositions containing (3s,js) tetrahydrocanabinol derivatives and some novel compounds of this type
US4847290A (en) * 1987-08-17 1989-07-11 Sumner Burstein Delta 1-thc-7-oic acid and analgesic and anti-inflammatory agents
US4973603A (en) * 1988-06-16 1990-11-27 Sumner Burstein Platelet activating factor antagonist and methods of use therefor
US5521215A (en) * 1989-11-07 1996-05-28 Ramot University Authority For Applied Research And Industrial Development Ltd. NMDA-blocking pharmaceuticals
US5338753A (en) 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics

Also Published As

Publication number Publication date
DE69923671T2 (de) 2006-03-16
JP2002511411A (ja) 2002-04-16
DK1071417T3 (da) 2005-06-13
DE69923671D1 (de) 2005-03-17
CA2328368C (en) 2009-03-31
EP1071417B1 (de) 2005-02-09
CA2328368A1 (en) 1999-10-21
US6410588B1 (en) 2002-06-25
EP1071417A1 (de) 2001-01-31
AU757945B2 (en) 2003-03-13
WO1999052524A1 (en) 1999-10-21
ES2241277T3 (es) 2005-10-16
IL138979A0 (en) 2001-11-25
GB9807639D0 (en) 1998-06-10
AU3436199A (en) 1999-11-01

Similar Documents

Publication Publication Date Title
ATE288749T1 (de) Verwendung von kannabidiol als entzündunghemmende mittel
DK0882021T3 (da) Nye phenanthridiner
ATE181913T1 (de) 2-(2-amino-3-methoxyphenyl)-4-oxo-4h-(1)- benzopyran für die behandlung von proliferativer erkrankungen
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
NO994330D0 (no) Metode for behandling av en tumor
ATE109459T1 (de) Cyclopropylderivate als lipoxygenase-inhibitoren.
TR200002248T2 (tr) Yeni dihidroksiheksanoik asit türevleri
ATE381327T1 (de) Cethylmyristat und cetylpalmitat zurbehandlung von ekzemen und/oder psoriasis
BG101126A (en) The use of muramylpeptide compounds
ATE234614T1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
DE59900286D1 (de) Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
DE69905602T2 (de) Arzneimittel zur vermeidung und umkehrung der atherosklerose bei säugetieren
ATE291425T1 (de) R-eliprodil zur behandlung von glaucoma
RU94024337A (ru) Антиметастатическое средство
BR0015424A (pt) Análogos de ácido hidroxieicosatetraenóico e, métodos de seu uso em tratamento de distúrbios de olho seco
DK1017377T3 (da) Anvendelse af 6,7-substituerede 2-aminotetraliner til behandling af af cytokin fremkaldte inflammatoriske tilstande
UA36485A (uk) Спосіб лікування генералізованого пародонтиту
CO5271719A1 (es) Composicion cosmetica adelgazante que contienen una substancia inductora de la produccion de il-6
DE60012718D1 (de) Prognose von ptp lar vermittelten krankheiten
GEP20012408B (en) Means for Treatment of Psoriasis
ECSP992841A (es) Nuevos derivados del acido dihidroxihexanoico
EA199800698A1 (ru) Способ лечения и фармацевтическая композиция
UA32360A (uk) Спосіб лікування розповсюджених хронічних дерматозів
GEU1998400Y (en) Ointment “Topokril” for Treating of Dermatitis
UA30524A (uk) Мазь для лікування гіперкератозів

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties